Drug Trial Radar · NCT04502030
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
247
Actual
Start
Oct 5, 2020
Primary completion
Sep 19, 2025
Study completion Sep 19, 2025
Sponsor
- Lead sponsor
- OctapharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
Conditions
- Chronic Lymphocytic Leukemia
- Hypogammaglobulinemia
Interventions
PanzygaBiological
Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Major InfectionsTime frame: From first treatment to the occurrence of a major infection or to the end of study visit. The median study duration of participants completing the study was 366 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Locations
84 sites in 12 countries. Site status is shown where the registry gives one.
Octapharma Research Site
St. Petersburg, Florida
Octapharma Research Site
Columbus, Georgia
Octapharma Research Site
Macon, Georgia
Octapharma Research Site
New Orleans, Louisiana
Octapharma Research Site
Baltimore, Maryland
Octapharma Research Site
Baltimore, Maryland
Octapharma Research Site
Detroit, Michigan
Octapharma Research Site
Rochester, Minnesota
Octapharma Research Site
Buffalo, New York
Octapharma Research Site
New York, New York
Octapharma Research Site
New York, New York
Octapharma Research Site
Shirley, New York
Octapharma Research Site
Durham, North Carolina
Octapharma Research Site
Charleston, South Carolina
Octapharma Research Site
Houston, Texas
Octapharma Research Site
Brno, Czechia
Octapharma Research Site
Hradec Králové, Czechia
Octapharma Research Site
Ostrava, Czechia
Octapharma Research Site
Aalborg, Denmark
Octapharma Research Site
Herning, Denmark
Octapharma Research Site
Roskilde, Denmark
Octapharma Research Site
Dortmund, Germany
Octapharma Research Site
Frankfurt, Germany
Octapharma Research Site
Kiel, Germany
Octapharma Research Site
Marburg, Germany
Octapharma Research Site
Athens, Greece
Octapharma Research Site
Athens, Greece
Octapharma Research Site
Athens, Greece
Octapharma Research Site
Ioannina, Greece
Octapharma Research Site
Pátrai, Greece
Octapharma Research Site
Thessaloniki, Greece
Octapharma Research Site
Budapest, Hungary
Octapharma Research Site
Debrecen, Hungary
Octapharma Research Site
Győr, Hungary
Octapharma Research Site
Kaposvár, Hungary
Octapharma Research Site
Nyíregyháza, Hungary
Octapharma Research Site
Haifa, Israel
Octapharma Research Site
Haifa, Israel
Octapharma Research Site
Petah Tikva, Israel
Octapharma Research Site
Castelfranco Veneto, Italy
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.